Case Study | November 07, 2014

Completion of TOBA-BTK Trial Enrollment to Treat CLI

The Tack Optimized Balloon Angioplasty - Below the Knee Study is completed

balloon angioplasty, clinical trial, clinical study, Intact Vascular, PAD

Nov. 7, 2014 — Intact Vascular, a medical device company and developer of products for minimally invasive peripheral vascular procedures, completed the Tack Optimized Balloon Angioplasty - Below the Knee (TOBA-BTK) Study. 

This multi-center pilot study focused on gathering data supporting the safety and performance of the Tack Endovascular System in subjects with critical limb ischemia (CLI) due to vascular disease below the knee. Thirty-five subjects were enrolled in this study, which targeted diseased tibial vessels for treatment.

Balloon angioplasty is the most common procedure performed to restore blood flow in these blocked arteries. However, post-angioplasty dissection often occurs at the treatment site, which increases the risk of thrombotic occlusion. The Tack device is designed to repair tissue tears at the site of post-angioplasty dissection.

The Tack Endovascular System has been designed:

1) to leave minimal foreign material in the artery

2) to apply only the minimum outward force required to repair tissue tears within the lumen

3) to allow “spot” treatment only where needed. The system is composed of a delivery catheter containing three self-expanding nitinol Tacks.

Assistant Professor Christian Wissgott, M.D., deputy chief, Institute of Diagnostic and Interventional Radiology, Westkuestenklinikum Heide, Germany, who was a leading enroller in the trial.

Peter Schneider, M.D., Intact Vascular chief medical officer and chief, vascular therapy at Kaiser Foundation Hospital in Honolulu, said, “Our best method for salvaging threatened limbs is to revascularize them using balloon angioplasty, but the current technique has limitations. The Tack Endovascular System has the potential to substantially improve outcomes for CLI patients by optimizing angioplasty.”

For more information: www.intactvascular.com 

 


Related Content

News | Peripheral Artery Disease (PAD)

Nov. 4, 2024 — Royal Philips recently announced enrollment of the first patient in the U.S. THOR IDE clinical trial ...

Home November 08, 2024
Home
News | Peripheral Artery Disease (PAD)

Sept. 16, 2024 – Shockwave Medical, Inc., part of Johnson & Johnson MedTech, has announced the full U.S. launch of the ...

Home September 16, 2024
Home
News | Peripheral Artery Disease (PAD)

Sept. 1, 2024 — September is Peripheral Artery Disease (PAD) Awareness Month, a time to educate and empower people to ...

Home September 04, 2024
Home
News | Peripheral Artery Disease (PAD)

May 16, 2024 — Timely diagnosis and proper management of peripheral artery disease (PAD), including coordinated care ...

Home May 16, 2024
Home
News | Peripheral Artery Disease (PAD)

May 8, 2024 — In a groundbreaking development, a study published in the Journal of Vascular Surgery reveals for the ...

Home May 08, 2024
Home
News | Peripheral Artery Disease (PAD)

March 20, 2024 — Biotronik has been granted Breakthrough Device Designation (BDD) from the US Food and Drug ...

Home March 20, 2024
Home
News | Peripheral Artery Disease (PAD)

February 12, 2024 — Sensome, a company pioneering the connected medical device revolution with the world’s smallest ...

Home February 12, 2024
Home
News | Peripheral Artery Disease (PAD)

November 10, 2023 —Getinge announced commercial availability of the iCast covered stent system in the United States for ...

Home November 10, 2023
Home
News | Peripheral Artery Disease (PAD)

October 24, 2023 — Four years ago, following a publication based on the limited data available, the U.S. Food and Drug ...

Home October 24, 2023
Home
News | Peripheral Artery Disease (PAD)

September 14, 2023 — LimFlow SA, a pioneer in the development of minimally-invasive technology for the treatment of ...

Home September 14, 2023
Home
Subscribe Now